Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Systems Medicine, a Cell Therapeutics subsidiary, has announced encouraging anti-tumor activity in cumulative positive preliminary results from a multicenter, dose-escalation Phase I trial combining cisplatin with brostallicin in patients with solid tumors that had relapsed or were resistant to front-line treatment.
Subscribe to our email newsletter
The preliminary results from the first 21 patients treated in the Phase I combination trial with cisplatin showed similar results, with 14 of the patients experiencing stable disease and half (50%) of those 14 patients having durable stable disease for more than six cycles of therapy. Toxicities were mainly hematological and were manageable and reversible in this heavily pretreated patient population.
Steven Weitman, managing director of Systems Medicine, said: “Our Phase I and II experience with brostallicin in over 160 patients demonstrates encouraging anti-tumor activity in a variety of solid tumors, with more than 50% of the patients experiencing at least disease stabilization.”